Matisse Pharmaceuticals B.V.

Matisse Pharmaceuticals

This biopharmaceutical company develops isupartob sodium, a heparin derivative designed to treat sepsis by neutralising cytotoxic histones in critically ill patients.

Adrenomed

This biopharmaceutical company develops monoclonal antibody therapies to restore vascular integrity for critically ill patients suffering from sepsis and septic shock.

Modus Therapeutics

This biotechnology company develops sevuparin to treat patients suffering from sepsis, septic shock, severe malaria and chronic systemic inflammation.

Inotrem

This biopharmaceutical company develops immunotherapies targeting the TREM-1 pathway for patients suffering from acute inflammatory syndromes such as septic shock.

PATH EX, Inc.

This company develops a medical device that removes bacteria and endotoxins from the bloodstream to treat sepsis patients in clinical settings.

SepsiScan

This company develops bedside imaging devices for real-time microcirculation monitoring and early sepsis diagnosis for intensive care units and hospitals.

AM Pharma

This biopharmaceutical company develops recombinant human alkaline phosphatase therapeutics to treat patients suffering from sepsis-associated acute kidney injury and other severe inflammatory conditions.

Advanced Perfusion Diagnostics

This company develops single-use devices for non-invasive, continuous microcirculation assessment and early sepsis detection for clinicians in critical care and surgical settings.